Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

29 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Silencing of GATA3 defines a novel stem cell-like subgroup of ETP-ALL.
Fransecky L, Neumann M, Heesch S, Schlee C, Ortiz-Tanchez J, Heller S, Mossner M, Schwartz S, Mochmann LH, Isaakidis K, Bastian L, Kees UR, Herold T, Spiekermann K, Gökbuget N, Baldus CD. Fransecky L, et al. J Hematol Oncol. 2016 Sep 22;9(1):95. doi: 10.1186/s13045-016-0324-8. J Hematol Oncol. 2016. PMID: 27658391 Free PMC article.
FLT3 mutations in early T-cell precursor ALL characterize a stem cell like leukemia and imply the clinical use of tyrosine kinase inhibitors.
Neumann M, Coskun E, Fransecky L, Mochmann LH, Bartram I, Sartangi NF, Heesch S, Gökbuget N, Schwartz S, Brandts C, Schlee C, Haas R, Dührsen U, Griesshammer M, Döhner H, Ehninger G, Burmeister T, Blau O, Thiel E, Hoelzer D, Hofmann WK, Baldus CD. Neumann M, et al. Among authors: fransecky l. PLoS One. 2013;8(1):e53190. doi: 10.1371/journal.pone.0053190. Epub 2013 Jan 24. PLoS One. 2013. PMID: 23359050 Free PMC article.
Low expression of T-cell transcription factor BCL11b predicts inferior survival in adult standard risk T-cell acute lymphoblastic leukemia patients.
Bartram I, Gökbuget N, Schlee C, Heesch S, Fransecky L, Schwartz S, Stuhlmann R, Schäfer-Eckhart K, Starck M, Reichle A, Hoelzer D, Baldus CD, Neumann M. Bartram I, et al. Among authors: fransecky l. J Hematol Oncol. 2014 Jul 15;7:51. doi: 10.1186/s13045-014-0051-y. J Hematol Oncol. 2014. PMID: 25023966 Free PMC article.
Outlook on PI3K/AKT/mTOR inhibition in acute leukemia.
Fransecky L, Mochmann LH, Baldus CD. Fransecky L, et al. Mol Cell Ther. 2015 Mar 20;3:2. doi: 10.1186/s40591-015-0040-8. eCollection 2015. Mol Cell Ther. 2015. PMID: 26056603 Free PMC article.
Acute myeloid leukemia in the elderly is characterized by a distinct genetic and epigenetic landscape.
Silva P, Neumann M, Schroeder MP, Vosberg S, Schlee C, Isaakidis K, Ortiz-Tanchez J, Fransecky LR, Hartung T, Türkmen S, Graf A, Krebs S, Blum H, Müller-Tidow C, Thiede C, Ehninger G, Serve H, Hecht J, Berdel WE, Greif PA, Röllig C, Baldus CD. Silva P, et al. Among authors: fransecky lr. Leukemia. 2017 Jul;31(7):1640-1644. doi: 10.1038/leu.2017.109. Epub 2017 Apr 3. Leukemia. 2017. PMID: 28366934 No abstract available.
Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial.
Platzbecker U, Middeke JM, Sockel K, Herbst R, Wolf D, Baldus CD, Oelschlägel U, Mütherig A, Fransecky L, Noppeney R, Bug G, Götze KS, Krämer A, Bochtler T, Stelljes M, Groth C, Schubert A, Mende M, Stölzel F, Borkmann C, Kubasch AS, von Bonin M, Serve H, Hänel M, Dührsen U, Schetelig J, Röllig C, Kramer M, Ehninger G, Bornhäuser M, Thiede C. Platzbecker U, et al. Among authors: fransecky l. Lancet Oncol. 2018 Dec;19(12):1668-1679. doi: 10.1016/S1470-2045(18)30580-1. Epub 2018 Nov 12. Lancet Oncol. 2018. PMID: 30442503 Clinical Trial.
Isocitrate dehydrogenase 1 mutation drives leukemogenesis by PDGFRA activation due to insulator disruption in acute myeloid leukemia (AML).
Steinhäuser S, Silva P, Lenk L, Beder T, Hartmann A, Hänzelmann S, Fransecky L, Neumann M, Bastian L, Lipinski S, Richter K, Bultmann M, Hübner E, Xia S, Röllig C, Vogiatzi F, Schewe DM, Yumiceba V, Schultz K, Spielmann M, Baldus CD. Steinhäuser S, et al. Among authors: fransecky l. Leukemia. 2023 Jan;37(1):134-142. doi: 10.1038/s41375-022-01751-6. Epub 2022 Nov 21. Leukemia. 2023. PMID: 36411356 Free PMC article.
Secondary-type mutations do not impact outcome in NPM1-mutated acute myeloid leukemia - implications for the European LeukemiaNet risk classification.
Eckardt JN, Bill M, Rausch C, Metzeler K, Spiekermann K, Stasik S, Sauer T, Scholl S, Hochhaus A, Crysandt M, Brümmendorf TH, Krug U, Wörmann B, Hiddemann W, Görlich D, Sauerland C, Steffen B, Einsele H, Neubauer A, Burchert A, Schäfer-Eckart K, Berdel WE, Schliemann C, Krause SW, Hänel M, Hanoun M, Kaufmann M, Fransecky L, Braess J, Ruhnke L, Schetelig J, Middeke JM, Serve H, Baldus CD, Platzbecker U, Müller-Tidow C, Bornhäuser M, Herold T, Thiede C, Röllig C. Eckardt JN, et al. Among authors: fransecky l. Leukemia. 2023 Nov;37(11):2282-2285. doi: 10.1038/s41375-023-02016-6. Epub 2023 Sep 7. Leukemia. 2023. PMID: 37679502 Free PMC article. No abstract available.
Molecular subgroups of T-cell acute lymphoblastic leukemia in adults treated according to pediatric-based GMALL protocols.
Neumann M, Beder T, Bastian L, Hänzelmann S, Bultmann M, Wolgast N, Hartmann A, Trautmann H, Ortiz-Tanchez J, Schlee C, Schroeder M, Fransecky L, Vosberg S, Fiedler W, Alakel N, Heberling L, Kondakci M, Starck M, Schwartz S, Raffel S, Müller-Tidow C, Schneller F, Reichle A, Burmeister T, Greif PA, Brüggemann M, Gökbuget N, Baldus CD. Neumann M, et al. Among authors: fransecky l. Leukemia. 2024 Jun;38(6):1213-1222. doi: 10.1038/s41375-024-02264-0. Epub 2024 May 14. Leukemia. 2024. PMID: 38744920 Free PMC article.
29 results